193 related articles for article (PubMed ID: 24826990)
21. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
George Priya Doss C; Zayed H
Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
[TBL] [Abstract][Full Text] [Related]
23. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
24. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
Kumar S; Biancotti JC; Matalon R; de Vellis J
J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
[TBL] [Abstract][Full Text] [Related]
25. Canavan disease: genomic organization and localization of human ASPA to 17p13-ter and conservation of the ASPA gene during evolution.
Kaul R; Balamurugan K; Gao GP; Matalon R
Genomics; 1994 May; 21(2):364-70. PubMed ID: 8088831
[TBL] [Abstract][Full Text] [Related]
26. Expression of aspartoacylase (ASPA) and Canavan disease.
Sommer A; Sass JO
Gene; 2012 Sep; 505(2):206-10. PubMed ID: 22750302
[TBL] [Abstract][Full Text] [Related]
27. Extensive aspartoacylase expression in the rat central nervous system.
Moffett JR; Arun P; Ariyannur PS; Garbern JY; Jacobowitz DM; Namboodiri AM
Glia; 2011 Oct; 59(10):1414-34. PubMed ID: 21598311
[TBL] [Abstract][Full Text] [Related]
28. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
29. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
[TBL] [Abstract][Full Text] [Related]
30. Human induced pluripotent stem cell line (SDQLCHi064-A) derived from a patient with Canavan disease carrying c.556_559dup GTTC and c.919delA mutations in the ASPA gene.
Liu N; Ge Y; Yang Y; Zhao F; Lv Y; Li Z; Dong R; Liu Y; Gai Z
Stem Cell Res; 2024 Apr; 76():103325. PubMed ID: 38309148
[TBL] [Abstract][Full Text] [Related]
31. Feline Spongy Encephalopathy With a Mutation in the
Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K
Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415
[TBL] [Abstract][Full Text] [Related]
32. Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.
Clarner T; Wieczorek N; Krauspe B; Jansen K; Beyer C; Kipp M
J Mol Neurosci; 2014 May; 53(1):22-30. PubMed ID: 24272958
[TBL] [Abstract][Full Text] [Related]
33. Canavan disease: a monogenic trait with complex genomic interaction.
Surendran S; Michals-Matalon K; Quast MJ; Tyring SK; Wei J; Ezell EL; Matalon R
Mol Genet Metab; 2003; 80(1-2):74-80. PubMed ID: 14567959
[TBL] [Abstract][Full Text] [Related]
34. Aspartoacylase gene knockout in the mouse: impact on reproduction.
Surendran S; Szucs S; Tyring SK; Matalon R
Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
[TBL] [Abstract][Full Text] [Related]
35. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
36. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
37. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
38. Does ASPA gene mutation in Canavan disease alter oligodendrocyte development? A tissue culture study of ASPA KO mice brain.
Kumar S; Sowmyalakshmi R; Daniels SL; Chang R; Surendran S; Matalon R; de Vellis J
Adv Exp Med Biol; 2006; 576():175-82; discussion 361-3. PubMed ID: 16802712
[No Abstract] [Full Text] [Related]
39. Structural modeling of p.V31F variant in the aspartoacylase gene.
Krishnamoorthy N; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702
[TBL] [Abstract][Full Text] [Related]
40. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
